FDA Rejects Sunscreen TEAs, Plans Public Hearing On Ingredient Review
This article was originally published in The Rose Sheet
Executive Summary
FDA announces that it has found data insufficient to affirm the safety of two of the eight pending time-and-extent applications for sunscreen actives – amiloxate and diethylhexyl butamido triazone, marketed under the trade names NeoHeliopan and Uvasorb HEB. The agency invites the public and manufacturers, to submit further information in support of the actives’ safety.